Helex
Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. The company's platform is powered ...
Valuation
$36.9M
Market implied
Share Price
N/A
Total Raised
$6.6M
Last Round
N/A